BioPharma Dive February 12, 2025
Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is unclear, supply chain experts said.
President Donald Trump’s tariff plans — both real and threatened — are roiling the medical device industry due to a complex supply chain dependent on offshore manufacturing.
The evolving policy caused whiplash when Trump ordered broad 25% tariffs on Canada and Mexico, before agreeing to postpone them for one month shortly after. Meanwhile, a new 10% tariff on imports from China has taken effect. Trump also threatened tariffs on the European Union. The president has said he will soon announce reciprocal tariffs on countries with levies on U.S. goods and, on Thursday, tasked U.S. agencies with preparing plans.
The...
Today's Sponsors
Today's Sponsor